Genetic Impact on Clinical Features in Parkinson’s Disease: A Study on SNCA-rs11931074

Table 1

Demographic data and clinical characteristics of carrier and noncarrier group of SNCA-rs11931074 in PD patients.

	Carriers		Noncarriers			SC/OR (95% CI)
		X ± S/N (F)		X ± S/N (F)
Age of enrollment	611	62.52 ± 12.88	113	64.80 ± 12.11	NA	NA
Age of onset	611	57.91 ± 13.44	113	60.02 ± 12.35	NA	NA
Disease course	611	4.61 ± 4.42	113	4.78 ± 3.97	0.700	0.446 (−1.046 to 0.703)
Gender, male	611	352 (57.6%)	113	64 (56.6%)	NA	NA
UPDRS I	522	1.76 ± 1.95	91	2.03 ± 2.04	0.226	−0.049
UPDRS II	522	12.41 ± 7.13	91	14.26 ± 6.90	0.035	−0.083
UPDRS III	553	27.42 ± 15.77	97	34.18 ± 16.53	≤0.001	−0.140
H-Y	452	2.26 ± 0.95	80	2.38 ± 0.89	0.487	−0.030
LEDD	469	546.78 ± 300.44	83	594.09 ± 115.41	0.164	−0.060
CCI	611	0.10 ± 0.37	113	0.21 ± 0.47	0.009	−0.097
Cognitive impairment	247	63 (25.5%)	39	12 (30.8%)	0.618	0.824 (0.386–1.761)
WO	403	51 (12.7%)	71	7 (9.9%)	0.502	1.331 (0.578–3.068)

UPDRS I, II, and III: Unified Parkinson’s Disease Rating Scale parts I, II, and III; H-Y: Hoehn and Yahr Scale; LEDD: levodopa equivalent daily dose; CCI: Charlson Comorbidity Index score; WO: wearing-off phenomenon evaluated by the 9-item wearing-off questionnaire (WOQ-9); N: the total number of carriers and noncarriers of SNCA-rs11931074 in PD patients; SC: standardized coefficient; OR: odds ratio; CI: confidence interval; NA: not available. ^#Standard error (95% CI). Cognitive impairment was assessed by Mini-Mental State Examination (MMSE). Numerical variable was presented as mean and standard deviation (X ± S); categorical variable was presented as the number of carriers or noncarriers and its relevant frequency separately [N (F)]. value <0.05 was considered statistically significant and is shown in bold.